Quick Answer
NEUROCRINE BIOSCIENCES INC reported Operating Income Loss of $619.10 million for the year ending 2025.
- NEUROCRINE BIOSCIENCES INC showed an increase of +8.5% in Operating Income Loss from 2024 to 2025.
- This data is from NEUROCRINE BIOSCIENCES INC's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), NEUROCRINE BIOSCIENCES INC's Operating Income Loss has grown by 1,253.5%.
- Historical annual values: Fiscal year 2025: $619.10 million | Fiscal year 2024: $570.50 million | Fiscal year 2023: $250.90 million | Fiscal year 2022: $249.00 million | Fiscal year 2021: $102.50 million | Fiscal year 2020: $163.00 million | Fiscal year 2019: $72.30 million | Fiscal year 2018: $36.80 million | Fiscal year 2017: -$131.36 million | Fiscal year 2016: -$147.37 million | Fiscal year 2015: -$94.20 million | Fiscal year 2014: -$64.41 million | Fiscal year 2013: -$49.68 million | Fiscal year 2012: $1.45 million | Fiscal year 2011: $33.92 million | Fiscal year 2010: -$13.72 million | Fiscal year 2009: -$53.67 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: